Efficacy and Safety of SPA100 (Fixed-dose Combination of Aliskiren/Amlodipine) in Patients With Essential Hypertension

Clinical trial NCT01237223 · COMPLETED

Trial details

NCT number: NCT01237223
Sponsor: Novartis
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Essential Hypertension

Start date: 2010-10-01
Primary completion: 2011-05-01
Enrollment: 1342

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.